Hello! You're looking at a policy document report on Overton
We track government policy, guidelines, think tank research, working papers and more to help our customers see the impact and influence of their work. Are you interested in seeing what information we have to offer? Request a free trial to our platform.
If you fund, produce or manage research or work to influence policy, we'd love to talk. Learn more on our homepage.
Enabling competition in pharmaceutical markets
Brookings Institution on
May 2nd 2017
Fiona Scott Morton and Lysle Boller
The United States, unlike many other industrialized nations, does not regulate the price of pharmaceutical products directly. There are advantages to this approach. The U.S. generic market is one o…
Topics in this document
Medicine
Health sciences
Pharmaceutical sciences
Health
Pharmacology
Healthcare industry
Generic drug
Pharmacy
Health care
Health policy
Medicare (United States)
Medicare Part D
Medication
Pharmaceutical industry
Food and Drug Administration
Orphan drug
Biosimilar
Pharmacy benefit management
Life sciences industry
Medicare Part D coverage gap
Health economics
Prescription drug
Industries
Public policy
Insurance
Business
Drugs
Economy
Pharmaceutics
Human activities
Related SDGs
Citations
Cited by 16 other policy documents
(12 of them are from other policy sources)
This document is made up of multiple PDFs
The references found in each have been combined below. If an item has been cited in more than one PDF then it'll appear more than once, linked to the relevant PDF and page number.